Novartis (NVS) Projected to Post Quarterly Earnings on Tuesday

Novartis (NYSE:NVS - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Tuesday, April 22nd. Analysts expect Novartis to post earnings of $2.07 per share and revenue of $12.92 billion for the quarter.

Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings results on Friday, January 31st. The company reported $1.98 EPS for the quarter, topping analysts' consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. On average, analysts expect Novartis to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Novartis Stock Performance

NYSE:NVS traded up $1.46 during trading on Thursday, reaching $111.59. The company's stock had a trading volume of 427,787 shares, compared to its average volume of 1,544,430. Novartis has a 12 month low of $96.06 and a 12 month high of $120.92. The firm has a market cap of $235.73 billion, a price-to-earnings ratio of 18.99, a price-to-earnings-growth ratio of 1.70 and a beta of 0.56. The firm has a 50 day moving average of $109.45 and a 200-day moving average of $106.26. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.84 and a current ratio of 1.04.

Novartis Announces Dividend

The business also recently declared a dividend, which was paid on Wednesday, March 12th. Investors of record on Wednesday, March 12th were given a dividend of $3.8695 per share. The ex-dividend date was Wednesday, March 12th. Novartis's payout ratio is currently 44.05%.

Analyst Ratings Changes

Several analysts have commented on the stock. StockNews.com raised shares of Novartis from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 8th. BNP Paribas raised shares of Novartis to a "strong-buy" rating in a report on Tuesday, April 15th. Morgan Stanley assumed coverage on Novartis in a report on Wednesday, February 12th. They set an "underweight" rating for the company. Deutsche Bank Aktiengesellschaft upgraded Novartis from a "hold" rating to a "buy" rating in a research note on Tuesday, February 4th. Finally, UBS Group reaffirmed a "neutral" rating on shares of Novartis in a research report on Thursday, February 13th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $123.38.

Hedge Funds Weigh In On Novartis

A hedge fund recently raised its stake in Novartis stock. Brighton Jones LLC boosted its stake in Novartis AG (NYSE:NVS - Free Report) by 76.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,153 shares of the company's stock after purchasing an additional 2,666 shares during the quarter. Brighton Jones LLC's holdings in Novartis were worth $599,000 as of its most recent filing with the Securities & Exchange Commission. 13.12% of the stock is currently owned by institutional investors and hedge funds.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.